Clinical Trials Logo
  1. Home
  2. Cutaneous T-cell Lymphoma (CTCL)
  3. NCT00476554

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL) Clinical Trial

Official title:
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Clinical Trial Summary

This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL).

Clinical Trial Description

This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2 systemic therapies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00476554
Study type Interventional
Source Cyclacel Pharmaceuticals, Inc.
Contact
Status Terminated
Phase Phase 2
Start date April 2007
Completion date March 1, 2012
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05156229 - A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL). Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT04072458 - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Phase 1
Active, not recruiting NCT02213861 - Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma Phase 2
Recruiting NCT05225584 - Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors Phase 1
Completed NCT00611208 - A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Phase 2
Completed NCT02580552 - Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Phase 1
Active, not recruiting NCT02616965 - A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Phase 1
Terminated NCT02314247 - Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma Phase 2
Withdrawn NCT01843998 - Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) Phase 2